James Wilson Biography and Net Worth

Director of Corcept Therapeutics

James N. Wilson has served as a director and as Chairman of our Board since 1999. From 2005 to 2018, he was also a member of the board of directors of NuGEN Technologies, Inc., a provider of systems for genomic analysis. From 2002 to 2009, Mr. Wilson served as the lead independent director of Amylin Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, and from 1996 to 2001, he was Chairman of the board of directors of Amira Medical, Inc., which was acquired by Hoffmann-La Roche A.G. From 1991 to 1994, Mr. Wilson was Chief Operating Officer of Syntex Corporation, which was acquired by Roche Holding, Ltd. From 1989 to 1990, Mr. Wilson was Chairman and Chief Executive Officer of Neurex Corporation, which was acquired by Elan Corporation plc. From 1982 to 1988, he was Chief Executive Officer of LifeScan, Inc., which was acquired by Johnson & Johnson Company. Mr. Wilson received his B.A. and M.B.A. from the University of Arizona.

What is James N. Wilson's net worth?: The estimated net worth of James N. Wilson is at least $126.90 million as of August 14th, 2026. Mr. Wilson owns 1,074,543 shares of Corcept Therapeutics stock worth more than $126,903,528 as of August 19th. This net worth evaluation does not reflect any other investments that Mr. Wilson may own. Learn More about James N. Wilson's net worth.
How do I contact James N. Wilson?: The corporate mailing address for Mr. Wilson and other Corcept Therapeutics executives is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. Corcept Therapeutics can also be reached via phone at (650) 327-3270 and via email at [email protected]. Learn More on James N. Wilson's contact information.
Has James N. Wilson been buying or selling shares of Corcept Therapeutics?: During the last ninety days, James N. Wilson has sold $1,114,300.00 in shares of Corcept Therapeutics stock. Most recently, James N. Wilson sold 10,000 shares of the business's stock in a transaction on Friday, August 14th. The shares were sold at an average price of $111.43, for a transaction totalling $1,114,300.00. Following the completion of the sale, the director now directly owns 1,074,543 shares of the company's stock, valued at $119,736,326.49. Learn More on James N. Wilson's trading history.
Who are Corcept Therapeutics' active insiders?: Corcept Therapeutics' insider roster includes G. Baker, Jr. (Director), Joseph Belanoff (CEO), William Guyer (Chief Development Officer), Hazel Hunt (Insider), Joseph Lyon (CAO), Sean Maduck (Insider), David Mahoney (Director), Atabak Mokari (CFO), Gary Robb (CFO), Daniel Swisher, Jr. (Director), and James Wilson (Director). Learn More on Corcept Therapeutics' active insiders.
Are insiders buying or selling shares of Corcept Therapeutics?: In the last year, Corcept Therapeutics insiders bought shares 1 times. They purchased a total of 100,000 shares worth more than $3,314,000.00. In the last year, insiders at the biotechnology company sold shares 45 times. They sold a total of 891,638 shares worth more than $69,214,911.16. The most recent insider tranaction occured on August, 14th when insider Sean Maduck sold 3,664 shares worth more than $419,491.36. Insiders at Corcept Therapeutics own 20.7% of the company. Learn More about insider trades at Corcept Therapeutics.
Information on this page was last updated on 8/14/2026.

James N. Wilson Insider Trading History at Corcept Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/14/2026	Sell	10,000	$111.43	$1,114,300.00	1,074,543
6/16/2026	Sell	10,000	$83.20	$832,000.00	1,094,543
11/11/2016	Sell	158,812	$8.51	$1,351,490.12
1/6/2016	Sell	1,188	$4.90	$5,821.20
11/12/2015	Sell	20,000	$4.90	$98,000.00
9/1/2015	Sell	10,000	$4.90	$49,000.00
7/1/2015	Sell	10,000	$6.06	$60,600.00
6/2/2015	Sell	10,000	$6.13	$61,300.00

James N. Wilson Buying and Selling Activity at Corcept Therapeutics

Corcept Therapeutics Company Overview

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Today's Range

Now: $118.10

$116.60

$119.95

50 Day Range

MA: $95.03

$78.12

$118.32

2 Week Range

Now: $118.10

$28.66

$122.21

Volume

803,234 shs

Average Volume

1,268,394 shs

Market Capitalization

$12.77 billion

P/E Ratio

281.20

Dividend Yield

N/A

Beta

0.45